Omnia Family Wealth LLC Has $408,000 Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Omnia Family Wealth LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 4.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,572 shares of the company’s stock after selling 182 shares during the period. Omnia Family Wealth LLC’s holdings in Merck & Co., Inc. were worth $408,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in MRK. Itau Unibanco Holding S.A. bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $39,000. Abich Financial Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the period. Quarry LP bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $42,000. Strategic Financial Concepts LLC raised its holdings in shares of Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after acquiring an additional 32,832 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in Merck & Co., Inc. by 47.5% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after acquiring an additional 122 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK stock traded down $0.42 during midday trading on Thursday, hitting $98.08. 2,082,709 shares of the company were exchanged, compared to its average volume of 8,846,551. Merck & Co., Inc. has a 52 week low of $97.90 and a 52 week high of $134.63. The firm has a market capitalization of $248.11 billion, a P/E ratio of 20.60, a PEG ratio of 1.41 and a beta of 0.40. The firm’s 50 day moving average price is $109.68 and its two-hundred day moving average price is $119.35. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. The company had revenue of $16.66 billion for the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.13 earnings per share. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 7.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRK shares. Truist Financial dropped their price target on Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Barclays reduced their price target on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, October 7th. Bank of America reduced their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. UBS Group lowered their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Sanford C. Bernstein initiated coverage on shares of Merck & Co., Inc. in a research note on Thursday, October 17th. They set a “market perform” rating and a $115.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.86.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.